Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Change in Cash (2016 - 2025)

Amicus Therapeutics' Change in Cash history spans 16 years, with the latest figure at $23.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 216.69% year-over-year to $23.5 million, compared with a TTM value of $600000.0 through Dec 2025, up 101.8%, and an annual FY2025 reading of $600000.0, up 101.8% over the prior year.
  • Change in Cash for Q4 2025 was $23.5 million at Amicus Therapeutics, down from $31.8 million in the prior quarter.
  • The five-year high for Change in Cash was $209.3 million in Q3 2021, with the low at -$139.6 million in Q4 2021.
  • Average Change in Cash over 5 years is $2.6 million, with a median of $800500.0 recorded in 2022.
  • Year-over-year, Change in Cash skyrocketed 2321.49% in 2023 and then crashed 5098.4% in 2025.
  • Tracing FOLD's Change in Cash over 5 years: stood at -$139.6 million in 2021, then rose by 8.02% to -$128.4 million in 2022, then surged by 87.39% to -$16.2 million in 2023, then decreased by 24.14% to -$20.1 million in 2024, then soared by 216.69% to $23.5 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Change in Cash are $23.5 million (Q4 2025), $31.8 million (Q3 2025), and -$22.7 million (Q2 2025).